Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cytokinetics Inc Market Cap
Based on ratings from 17 stock analysts, the Cytokinetics Inc stock price is expected to increase by 17.03% in 12 months. This is calculated by using the average 12-month stock price forecast for Cytokinetics Inc. The lowest target is $50.00 and the highest is $122.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 17 Wall Street analysts have assigned CYTK 14 buy ratings, 3 hold ratings, and 0 sell ratings. This means that analysts expect Cytokinetics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CYTK. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| srikripa devarakonda Truist Financial | Buy | $86.0 | maintained | Feb 5, 2024 |
| salim syed Mizuho Securities | Buy | $103.0 | rated | Feb 5, 2024 |
| mayank mamtani B.Riley Financial | Buy | $122.0 | reiterated | Feb 5, 2024 |
| joseph pantginis H.C. Wainwright | Buy | $94.0 | reiterated | Jan 25, 2024 |
| akash tewari Jefferies | Buy | $95.0 | maintained | Jan 25, 2024 |
| jason zemansky Bank of America Securities | Hold | $85.0 | maintained | Jan 25, 2024 |
| ashwani verma UBS | Hold | $92.0 | downgraded | Jan 24, 2024 |
| roanna ruiz Leerink Partners | Buy | None | maintained | Jan 8, 2024 |
| jeffrey hung Morgan Stanley | Hold | $90.0 | downgraded | Jan 5, 2024 |
| tessa romero J.P. Morgan | Buy | $78.0 | maintained | Jan 2, 2024 |
| justin kim Oppenheimer | Buy | $54.0 | reiterated | Dec 27, 2023 |
| charles duncan Cantor Fitzgerald | Buy | $101.0 | maintained | Dec 27, 2023 |
| chris shibutani Goldman Sachs | Buy | $85.0 | maintained | Dec 27, 2023 |
| jason butler JMP Securities | Buy | $110.0 | reiterated | Dec 27, 2023 |
| serge belanger Needham | Buy | $108.0 | maintained | Dec 27, 2023 |
| carter gould Barclays | Buy | $100.0 | rated | Dec 27, 2023 |
| yasmeen rahimi Piper Sandler | Buy | $69.0 | maintained | Dec 5, 2023 |
| paul choi Goldman Sachs | Buy | $50.0 | maintained | Dec 3, 2023 |
| madhu kumar Goldman Sachs | Buy | $53.0 | reiterated | May 4, 2023 |
| jason goldberg Barclays | Buy | $58.0 | rated | Apr 3, 2023 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
When did it IPO
2004
Staff Count
409
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Robert I. Blum
Market Cap
$7.54B
In 2023, CYTK generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CYTK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
DUOL-USD
$174.26
$41.06
ACHC-USD
$84.63
$73.7
LYFT-USD
$17.91
APLS-USD
$67.59
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
